Head-to-head comparison of [18F]FDG PET and [68Ga]Ga-FAPI-04 PET in the diagnosis of gastric and pancreatic cancer: a systematic review and meta-analysis
{"title":"Head-to-head comparison of [18F]FDG PET and [68Ga]Ga-FAPI-04 PET in the diagnosis of gastric and pancreatic cancer: a systematic review and meta-analysis","authors":"Wanrun Xie, Bo Li, Zhenzhen Hong, Yi Zhang","doi":"10.1007/s40336-024-00633-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Our meta-analysis aimed to compare the positivity rates of [<sup>68</sup>Ga]Ga-FAPI-04 PET and [<sup>18</sup>F]FDG PET in gastric and pancreatic cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We conducted a comprehensive search of PubMed, Embase, and Web of Science databases up to May 2023. The selected studies focused on evaluating the positivity rates of [<sup>18</sup>F]FDG PET and [<sup>68</sup>Ga]Ga-FAPI-04 PET in detecting gastric and pancreatic cancer.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 2,401 studies were screened and 13 articles were finally included. The positivity rates of [<sup>18</sup>F]FDG PET for primary gastric cancer, lymph node and peritoneal metastases were 0.74 [95% confidence interval (CI): 0.55–0.89], 0.49 (95% CI: 0.33–0.65) and 0.52 (95% CI: 0.37–0.67), respectively. On the other hand, [<sup>68</sup>Ga]Ga-FAPI-04 PET demonstrated significantly higher positivity rates at 0.98 (95% CI: 0.92-1.00), 0.76 (95% CI: 0.60–0.89) and 0.99 (95% CI: 0.93-1.00) (<i>P</i> < 0.01,<i>P</i> = 0.02, <i>P</i> < 0.01), respectively. For pancreatic cancer, [<sup>18</sup>F]FDG PET showed positivity rates of 0.93 (95% CI: 0.76-1.00) and 0.46 (95% CI: 0.23–0.69) for primary cancer and lymph node metastases, respectively. In comparison, [<sup>68</sup>Ga]Ga-FAPI-04 PET showed similar positivity rates of 1.00 (95% CI: 0.94-1.00) and 0.68 (95% CI: 0.40–0.90), (<i>P</i> = 0.27, 0.23). There was no significant difference in histopathological positivity rates for signet ring cell carcinoma and TNM stages I and II-IV (<i>P</i> = 0.96, 0.85,0.56).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>[<sup>68</sup>Ga]Ga-FAPI-04 PET exhibited a higher positivity rate compared to [<sup>18</sup>F]FDG PET in the detection of primary gastric cancer, lymph node and peritoneal metastases. For pancreatic cancer, both [<sup>18</sup>F]FDG PET and [<sup>68</sup>Ga]Ga-FAPI-04 PET demonstrated comparable, high positivity rates for primary cancer diagnosis and lymph node metastasis detection. There is still a requirement for more extensive and forward-looking research in this field.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"1 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-024-00633-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Our meta-analysis aimed to compare the positivity rates of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET in gastric and pancreatic cancer.
Methods
We conducted a comprehensive search of PubMed, Embase, and Web of Science databases up to May 2023. The selected studies focused on evaluating the positivity rates of [18F]FDG PET and [68Ga]Ga-FAPI-04 PET in detecting gastric and pancreatic cancer.
Results
A total of 2,401 studies were screened and 13 articles were finally included. The positivity rates of [18F]FDG PET for primary gastric cancer, lymph node and peritoneal metastases were 0.74 [95% confidence interval (CI): 0.55–0.89], 0.49 (95% CI: 0.33–0.65) and 0.52 (95% CI: 0.37–0.67), respectively. On the other hand, [68Ga]Ga-FAPI-04 PET demonstrated significantly higher positivity rates at 0.98 (95% CI: 0.92-1.00), 0.76 (95% CI: 0.60–0.89) and 0.99 (95% CI: 0.93-1.00) (P < 0.01,P = 0.02, P < 0.01), respectively. For pancreatic cancer, [18F]FDG PET showed positivity rates of 0.93 (95% CI: 0.76-1.00) and 0.46 (95% CI: 0.23–0.69) for primary cancer and lymph node metastases, respectively. In comparison, [68Ga]Ga-FAPI-04 PET showed similar positivity rates of 1.00 (95% CI: 0.94-1.00) and 0.68 (95% CI: 0.40–0.90), (P = 0.27, 0.23). There was no significant difference in histopathological positivity rates for signet ring cell carcinoma and TNM stages I and II-IV (P = 0.96, 0.85,0.56).
Conclusion
[68Ga]Ga-FAPI-04 PET exhibited a higher positivity rate compared to [18F]FDG PET in the detection of primary gastric cancer, lymph node and peritoneal metastases. For pancreatic cancer, both [18F]FDG PET and [68Ga]Ga-FAPI-04 PET demonstrated comparable, high positivity rates for primary cancer diagnosis and lymph node metastasis detection. There is still a requirement for more extensive and forward-looking research in this field.
期刊介绍：
Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
